Nurse Practitioner - New levofloxacin use
Ortho-McNeil’s levofloxacin (Levaquin) tablets and injection are now approved for the treatment of penicillin-resistant Streptococcus pneumoniae in community acquired pneumonia (CAP). Levofloxacin is already approved for the treatment of mild, moderate, and severe CAP caused by other pathogens, acute maxillary sinusitis, and acute bacterial exacerbation of chronic bronchitis, as well as mild to moderate uncomplicated skin and skin structure infections, complicated urinary tract infections (UTIs), acute pyelonephritis, and uncomplicated UTIs.
Nausea and diarrhea were the most common adverse events associated with levofloxacin in clinical trials.
Related Results
Alpharma launches unit-dosed sucralfate suspensionTry antacids, sucralfate first for gastroesophageal reflux diseaseBleeding and pneumonia in intensive care patients given ranitidine and…Trust, E-innovation and Leadership in ChangeForeign Banks in United States Since World War II: A Useful Fringe
Antacids containing magnesium or aluminum, as well as sucralfate, metal cations (such as iron), multivitamin preparations with zinc, and didanosine (Videx) chewable/buffered tablets or pediatric powder for oral solution should be taken at least 2 hours before or 2 hours after levofloxacin administration.
Copyright Springhouse Corporation Jun 2000
Provided by ProQuest Information and Learning Company. All rights Reserved
